Product Approval and Public Health at the US Food and Drug Administration

被引：2
作者：
Lurie, Peter [1 ]
Sharfstein, Joshua M. [2 ]
机构：
[1] Ctr Sci Publ Interest, Washington, DC USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 615 N Wolfe St,W1033F, Baltimore, MD 21205 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2021年 / 326卷 / 24期
关键词：
D O I：
10.1001/jama.2021.22354
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2469 / 2470
页数：2
相关论文
共 6 条
[1]  
[Anonymous], 2017, FDA REQ REM OP ER RI
[2]  
Food and Drug Administration, BEN RISK ASS NEW DRU
[3]  
Food and Drug Administration, 209 GFI FOOD DRUG AD
[4]   Marshaling FDA Benefit-Risk Expertise to Address the Current Opioid Abuse Epidemic [J].
Gottlieb, Scott ;
Woodcock, Janet .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (05) :421-422
[5]  
National Academies of Sciences Engineering and Medicine, 2017, PAIN MAN OP EP BAL S
[6]  
Zettler PJ, 2018, FOOD DRUG LAW J, V73, P221
1